Elanco (ELAN) Q3 2026 Earnings Call Transcript
Elanco (ELAN) reported Q3 2026 earnings, exceeding guidance with 9% revenue growth. Key drivers were International Pet Health (up 17%) and US Pet Health (up 13%), led by products like Zenrelia and Credelio Cuatro. Innovation revenue reached $328M, up 40% YoY. The company raised full-year innovation revenue targets to $1.275B and increased overall guidance. Zenrelia achieved record market share in the US and is nearing blockbuster status internationally.
How this was made
The 30-second read
Why it matters
The company exceeded revenue, adjusted EBITDA and EPS guidance, raised full‑year outlook, and highlighted strong growth in its Zenrelia and Quattro product lines.
Market read
Earnings beat and guidance raise are likely to move ELAN stock and influence the animal health sector.
What to watch
Potential supply‑chain constraints or competitive pricing pressure not discussed in the call.
Background
Elanco Animal Health's Q3 2026 earnings call transcript released by Yahoo Finance.
Ticker impact
Elanco reported Q3 2026 earnings beating the high end of guidance and raised full-year guidance, providing fresh material data.
likely upward pressure as investors price in stronger revenue and EBITDA outlook
Guidance lift and beat are primary disclosures; market typically reacts positively to such news.
Market effects
Pet health and animal health sector may see broader optimism from Elanco's strong performance.
U.S. and international animal health markets could benefit from higher demand signals.
Modest, limited to specialty agriculture and pet‑care segments.
Counterpoint
If the beat is already priced in, the stock could face short‑cover pull‑back.
Key entities
- companyElanco Animal Health
U.S. listed animal health company (ticker ELAN).
